

Global Peripherally Acting Anti-Obesity Drug Market Research Report 2024(Status and Outlook)

https://marketpublishers.com/r/G995E7C283AAEN.html

Date: January 2024 Pages: 124 Price: US\$ 3,200.00 (Single User License) ID: G995E7C283AAEN

Abstracts

Report Overview

This report provides a deep insight into the global Peripherally Acting Anti-Obesity Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Peripherally Acting Anti-Obesity Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Peripherally Acting Anti-Obesity Drug market in any manner.

Global Peripherally Acting Anti-Obesity Drug Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding



the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Novo Nordisk A/S

Pfizer Inc.

Boehringer Ingelheim International GmbH

KVK Tech Inc.

Gelesis Holdings

Vivus LLC.

Currax Pharmaceuticals LLC

GlaxoSmithKline plc

CHEPLAPHARM Arzneimittel GmbH

Rhythm Pharmaceuticals

Market Segmentation (by Type)

Prescription Drugs

Non-prescription Drugs

Market Segmentation (by Application)

Hospital Pharmacies

Retail Pharmacies



Online Pharmacies

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Peripherally Acting Anti-Obesity Drug Market

Overview of the regional outlook of the Peripherally Acting Anti-Obesity Drug Market:

Key Reasons to Buy this Report:



Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the



years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Peripherally Acting Anti-Obesity Drug Market and its likely evolution in the short to midterm, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.



Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.



Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

- 1.1 Market Definition and Statistical Scope of Peripherally Acting Anti-Obesity Drug
- 1.2 Key Market Segments
- 1.2.1 Peripherally Acting Anti-Obesity Drug Segment by Type
- 1.2.2 Peripherally Acting Anti-Obesity Drug Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats

2 PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Peripherally Acting Anti-Obesity Drug Market Size (M USD) Estimates and Forecasts (2019-2030)

2.1.2 Global Peripherally Acting Anti-Obesity Drug Sales Estimates and Forecasts (2019-2030)

- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

3 PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET COMPETITIVE LANDSCAPE

3.1 Global Peripherally Acting Anti-Obesity Drug Sales by Manufacturers (2019-2024)

3.2 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Manufacturers (2019-2024)

3.3 Peripherally Acting Anti-Obesity Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Peripherally Acting Anti-Obesity Drug Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Peripherally Acting Anti-Obesity Drug Sales Sites, Area Served, Product Type

3.6 Peripherally Acting Anti-Obesity Drug Market Competitive Situation and Trends3.6.1 Peripherally Acting Anti-Obesity Drug Market Concentration Rate



3.6.2 Global 5 and 10 Largest Peripherally Acting Anti-Obesity Drug Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 PERIPHERALLY ACTING ANTI-OBESITY DRUG INDUSTRY CHAIN ANALYSIS

- 4.1 Peripherally Acting Anti-Obesity Drug Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Market Restraints
- 5.5 Industry News
 - 5.5.1 New Product Developments
 - 5.5.2 Mergers & Acquisitions
 - 5.5.3 Expansions
- 5.5.4 Collaboration/Supply Contracts
- 5.6 Industry Policies

6 PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2019-2024)

6.3 Global Peripherally Acting Anti-Obesity Drug Market Size Market Share by Type (2019-2024)

6.4 Global Peripherally Acting Anti-Obesity Drug Price by Type (2019-2024)

7 PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)



7.2 Global Peripherally Acting Anti-Obesity Drug Market Sales by Application (2019-2024)

7.3 Global Peripherally Acting Anti-Obesity Drug Market Size (M USD) by Application (2019-2024)

7.4 Global Peripherally Acting Anti-Obesity Drug Sales Growth Rate by Application (2019-2024)

8 PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET SEGMENTATION BY REGION

8.1 Global Peripherally Acting Anti-Obesity Drug Sales by Region

- 8.1.1 Global Peripherally Acting Anti-Obesity Drug Sales by Region
- 8.1.2 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region
- 8.2 North America
 - 8.2.1 North America Peripherally Acting Anti-Obesity Drug Sales by Country
 - 8.2.2 U.S.
 - 8.2.3 Canada
 - 8.2.4 Mexico
- 8.3 Europe
 - 8.3.1 Europe Peripherally Acting Anti-Obesity Drug Sales by Country
 - 8.3.2 Germany
 - 8.3.3 France
 - 8.3.4 U.K.
 - 8.3.5 Italy
 - 8.3.6 Russia
- 8.4 Asia Pacific

8.4.1 Asia Pacific Peripherally Acting Anti-Obesity Drug Sales by Region

- 8.4.2 China
- 8.4.3 Japan
- 8.4.4 South Korea
- 8.4.5 India
- 8.4.6 Southeast Asia
- 8.5 South America

8.5.1 South America Peripherally Acting Anti-Obesity Drug Sales by Country

- 8.5.2 Brazil
- 8.5.3 Argentina
- 8.5.4 Columbia
- 8.6 Middle East and Africa
 - 8.6.1 Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Region



8.6.2 Saudi Arabia

- 8.6.3 UAE
- 8.6.4 Egypt
- 8.6.5 Nigeria
- 8.6.6 South Africa

9 KEY COMPANIES PROFILE

- 9.1 Novo Nordisk A/S
 - 9.1.1 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Basic Information
- 9.1.2 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Overview
- 9.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Market Performance
- 9.1.4 Novo Nordisk A/S Business Overview
- 9.1.5 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug SWOT Analysis
- 9.1.6 Novo Nordisk A/S Recent Developments

9.2 Pfizer Inc.

- 9.2.1 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Basic Information
- 9.2.2 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Overview
- 9.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Market Performance
- 9.2.4 Pfizer Inc. Business Overview
- 9.2.5 Pfizer Inc. Peripherally Acting Anti-Obesity Drug SWOT Analysis
- 9.2.6 Pfizer Inc. Recent Developments
- 9.3 Boehringer Ingelheim International GmbH

9.3.1 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Basic Information

9.3.2 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Overview

9.3.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Market Performance

9.3.4 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug SWOT Analysis

- 9.3.5 Boehringer Ingelheim International GmbH Business Overview
- 9.3.6 Boehringer Ingelheim International GmbH Recent Developments 9.4 KVK Tech Inc.
- 9.4.1 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Basic Information
- 9.4.2 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Overview

9.4.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Market Performance



9.4.4 KVK Tech Inc. Business Overview

9.4.5 KVK Tech Inc. Recent Developments

9.5 Gelesis Holdings

9.5.1 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Basic Information

9.5.2 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Overview

9.5.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Market Performance

9.5.4 Gelesis Holdings Business Overview

9.5.5 Gelesis Holdings Recent Developments

9.6 Vivus LLC.

9.6.1 Vivus LLC. Peripherally Acting Anti-Obesity Drug Basic Information

9.6.2 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Overview

9.6.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Market Performance

9.6.4 Vivus LLC. Business Overview

9.6.5 Vivus LLC. Recent Developments

9.7 Currax Pharmaceuticals LLC

9.7.1 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Basic Information

9.7.2 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Overview

9.7.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Market Performance

9.7.4 Currax Pharmaceuticals LLC Business Overview

9.7.5 Currax Pharmaceuticals LLC Recent Developments

9.8 GlaxoSmithKline plc

9.8.1 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Basic Information

9.8.2 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Overview

9.8.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Market Performance

9.8.4 GlaxoSmithKline plc Business Overview

9.8.5 GlaxoSmithKline plc Recent Developments

9.9 CHEPLAPHARM Arzneimittel GmbH

9.9.1 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Basic Information

9.9.2 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Overview

9.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Market Performance

9.9.4 CHEPLAPHARM Arzneimittel GmbH Business Overview



9.9.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments

9.10 Rhythm Pharmaceuticals

9.10.1 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Basic Information

9.10.2 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Overview

9.10.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Market Performance

9.10.4 Rhythm Pharmaceuticals Business Overview

9.10.5 Rhythm Pharmaceuticals Recent Developments

10 PERIPHERALLY ACTING ANTI-OBESITY DRUG MARKET FORECAST BY REGION

10.1 Global Peripherally Acting Anti-Obesity Drug Market Size Forecast

10.2 Global Peripherally Acting Anti-Obesity Drug Market Forecast by Region

10.2.1 North America Market Size Forecast by Country

10.2.2 Europe Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country

10.2.3 Asia Pacific Peripherally Acting Anti-Obesity Drug Market Size Forecast by Region

10.2.4 South America Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country

10.2.5 Middle East and Africa Forecasted Consumption of Peripherally Acting Anti-Obesity Drug by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)

11.1 Global Peripherally Acting Anti-Obesity Drug Market Forecast by Type (2025-2030)

11.1.1 Global Forecasted Sales of Peripherally Acting Anti-Obesity Drug by Type (2025-2030)

11.1.2 Global Peripherally Acting Anti-Obesity Drug Market Size Forecast by Type (2025-2030)

11.1.3 Global Forecasted Price of Peripherally Acting Anti-Obesity Drug by Type (2025-2030)

11.2 Global Peripherally Acting Anti-Obesity Drug Market Forecast by Application (2025-2030)

11.2.1 Global Peripherally Acting Anti-Obesity Drug Sales (Kilotons) Forecast by Application

11.2.2 Global Peripherally Acting Anti-Obesity Drug Market Size (M USD) Forecast by



Application (2025-2030)

12 CONCLUSION AND KEY FINDINGS



List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Peripherally Acting Anti-Obesity Drug Market Size Comparison by Region (M USD)

Table 5. Global Peripherally Acting Anti-Obesity Drug Sales (Kilotons) by Manufacturers (2019-2024)

Table 6. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Peripherally Acting Anti-Obesity Drug Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Peripherally Acting Anti-Obesity Drug Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripherally Acting Anti-Obesity Drug as of 2022)

Table 10. Global Market Peripherally Acting Anti-Obesity Drug Average Price (USD/Ton) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Peripherally Acting Anti-Obesity Drug Sales Sites and Area Served

Table 12. Manufacturers Peripherally Acting Anti-Obesity Drug Product Type

- Table 13. Global Peripherally Acting Anti-Obesity Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 14. Mergers & Acquisitions, Expansion Plans
- Table 15. Industry Chain Map of Peripherally Acting Anti-Obesity Drug
- Table 16. Market Overview of Key Raw Materials
- Table 17. Midstream Market Analysis
- Table 18. Downstream Customer Analysis
- Table 19. Key Development Trends
- Table 20. Driving Factors
- Table 21. Peripherally Acting Anti-Obesity Drug Market Challenges
- Table 22. Global Peripherally Acting Anti-Obesity Drug Sales by Type (Kilotons)

Table 23. Global Peripherally Acting Anti-Obesity Drug Market Size by Type (M USD)

Table 24. Global Peripherally Acting Anti-Obesity Drug Sales (Kilotons) by Type (2019-2024)

Table 25. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type



(2019-2024)

Table 26. Global Peripherally Acting Anti-Obesity Drug Market Size (M USD) by Type (2019-2024)

Table 27. Global Peripherally Acting Anti-Obesity Drug Market Size Share by Type (2019-2024)

Table 28. Global Peripherally Acting Anti-Obesity Drug Price (USD/Ton) by Type (2019-2024)

Table 29. Global Peripherally Acting Anti-Obesity Drug Sales (Kilotons) by Application

Table 30. Global Peripherally Acting Anti-Obesity Drug Market Size by Application

Table 31. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2019-2024) & (Kilotons)

Table 32. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2019-2024)

Table 33. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2019-2024) & (M USD)

Table 34. Global Peripherally Acting Anti-Obesity Drug Market Share by Application (2019-2024)

Table 35. Global Peripherally Acting Anti-Obesity Drug Sales Growth Rate by Application (2019-2024)

Table 36. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2019-2024) & (Kilotons)

Table 37. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2019-2024)

Table 38. North America Peripherally Acting Anti-Obesity Drug Sales by Country(2019-2024) & (Kilotons)

Table 39. Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2019-2024) & (Kilotons)

Table 40. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales by Region (2019-2024) & (Kilotons)

Table 41. South America Peripherally Acting Anti-Obesity Drug Sales by Country (2019-2024) & (Kilotons)

Table 42. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Region (2019-2024) & (Kilotons)

Table 43. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Basic InformationTable 44. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Overview

Table 45. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales (Kilotons),

Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)

Table 46. Novo Nordisk A/S Business Overview

Table 47. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug SWOT Analysis



Table 48. Novo Nordisk A/S Recent Developments

Table 49. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Basic Information

Table 50. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Overview

Table 51. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales (Kilotons), Revenue (M

USD), Price (USD/Ton) and Gross Margin (2019-2024)

Table 52. Pfizer Inc. Business Overview

Table 53. Pfizer Inc. Peripherally Acting Anti-Obesity Drug SWOT Analysis

Table 54. Pfizer Inc. Recent Developments

Table 55. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Basic Information

Table 56. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Overview

Table 57. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)

Table 58. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug SWOT Analysis

Table 59. Boehringer Ingelheim International GmbH Business Overview

Table 60. Boehringer Ingelheim International GmbH Recent Developments

Table 61. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Basic Information

Table 62. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Overview

Table 63. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales (Kilotons),

Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)

Table 64. KVK Tech Inc. Business Overview

Table 65. KVK Tech Inc. Recent Developments

Table 66. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Basic Information

Table 67. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Overview

Table 68. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales (Kilotons),

Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)

Table 69. Gelesis Holdings Business Overview

Table 70. Gelesis Holdings Recent Developments

Table 71. Vivus LLC. Peripherally Acting Anti-Obesity Drug Basic Information

Table 72. Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Overview

Table 73. Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales (Kilotons), Revenue

(M USD), Price (USD/Ton) and Gross Margin (2019-2024)

Table 74. Vivus LLC. Business Overview

Table 75. Vivus LLC. Recent Developments

Table 76. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Basic Information



Table 77. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Overview

Table 78. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)

Table 79. Currax Pharmaceuticals LLC Business Overview

Table 80. Currax Pharmaceuticals LLC Recent Developments

Table 81. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Basic Information

Table 82. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Overview

Table 83. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales (Kilotons),

Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)

 Table 84. GlaxoSmithKline plc Business Overview

Table 85. GlaxoSmithKline plc Recent Developments

Table 86. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity DrugBasic Information

Table 87. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Overview

Table 88. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)

 Table 89. CHEPLAPHARM Arzneimittel GmbH Business Overview

Table 90. CHEPLAPHARM Arzneimittel GmbH Recent Developments

Table 91. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug BasicInformation

Table 92. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Overview

 Table 93. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales

(Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)

Table 94. Rhythm Pharmaceuticals Business Overview

Table 95. Rhythm Pharmaceuticals Recent Developments

Table 96. Global Peripherally Acting Anti-Obesity Drug Sales Forecast by Region(2025-2030) & (Kilotons)

Table 97. Global Peripherally Acting Anti-Obesity Drug Market Size Forecast by Region (2025-2030) & (M USD)

Table 98. North America Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2025-2030) & (Kilotons)

Table 99. North America Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country (2025-2030) & (M USD)

Table 100. Europe Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2025-2030) & (Kilotons)

Table 101. Europe Peripherally Acting Anti-Obesity Drug Market Size Forecast by



Country (2025-2030) & (M USD)

Table 102. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales Forecast by Region (2025-2030) & (Kilotons)

Table 103. Asia Pacific Peripherally Acting Anti-Obesity Drug Market Size Forecast by Region (2025-2030) & (M USD)

Table 104. South America Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2025-2030) & (Kilotons)

Table 105. South America Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country (2025-2030) & (M USD)

Table 106. Middle East and Africa Peripherally Acting Anti-Obesity Drug Consumption Forecast by Country (2025-2030) & (Units)

Table 107. Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country (2025-2030) & (M USD)

Table 108. Global Peripherally Acting Anti-Obesity Drug Sales Forecast by Type (2025-2030) & (Kilotons)

Table 109. Global Peripherally Acting Anti-Obesity Drug Market Size Forecast by Type (2025-2030) & (M USD)

Table 110. Global Peripherally Acting Anti-Obesity Drug Price Forecast by Type (2025-2030) & (USD/Ton)

Table 111. Global Peripherally Acting Anti-Obesity Drug Sales (Kilotons) Forecast by Application (2025-2030)

Table 112. Global Peripherally Acting Anti-Obesity Drug Market Size Forecast by Application (2025-2030) & (M USD)





List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Peripherally Acting Anti-Obesity Drug

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Peripherally Acting Anti-Obesity Drug Market Size (M USD), 2019-2030 Figure 5. Global Peripherally Acting Anti-Obesity Drug Market Size (M USD) (2019-2030)

Figure 6. Global Peripherally Acting Anti-Obesity Drug Sales (Kilotons) & (2019-2030)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Peripherally Acting Anti-Obesity Drug Market Size by Country (M USD)

Figure 11. Peripherally Acting Anti-Obesity Drug Sales Share by Manufacturers in 2023

Figure 12. Global Peripherally Acting Anti-Obesity Drug Revenue Share by Manufacturers in 2023

Figure 13. Peripherally Acting Anti-Obesity Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 14. Global Market Peripherally Acting Anti-Obesity Drug Average Price (USD/Ton) of Key Manufacturers in 2023

Figure 15. The Global 5 and 10 Largest Players: Market Share by Peripherally Acting Anti-Obesity Drug Revenue in 2023

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Peripherally Acting Anti-Obesity Drug Market Share by Type

Figure 18. Sales Market Share of Peripherally Acting Anti-Obesity Drug by Type (2019-2024)

Figure 19. Sales Market Share of Peripherally Acting Anti-Obesity Drug by Type in 2023 Figure 20. Market Size Share of Peripherally Acting Anti-Obesity Drug by Type (2019-2024)

Figure 21. Market Size Market Share of Peripherally Acting Anti-Obesity Drug by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Peripherally Acting Anti-Obesity Drug Market Share by Application

Figure 24. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2019-2024)

Figure 25. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application in 2023



Figure 26. Global Peripherally Acting Anti-Obesity Drug Market Share by Application (2019-2024)

Figure 27. Global Peripherally Acting Anti-Obesity Drug Market Share by Application in 2023

Figure 28. Global Peripherally Acting Anti-Obesity Drug Sales Growth Rate by Application (2019-2024)

Figure 29. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2019-2024)

Figure 30. North America Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons)

Figure 31. North America Peripherally Acting Anti-Obesity Drug Sales Market Share by Country in 2023

Figure 32. U.S. Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons)

Figure 33. Canada Peripherally Acting Anti-Obesity Drug Sales (Kilotons) and Growth Rate (2019-2024)

Figure 34. Mexico Peripherally Acting Anti-Obesity Drug Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons)

Figure 36. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share by Country in 2023

Figure 37. Germany Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons)

Figure 38. France Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons)

Figure 39. U.K. Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons)

Figure 40. Italy Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons)

Figure 41. Russia Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons)

Figure 42. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (Kilotons)

Figure 43. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales Market Share by Region in 2023

Figure 44. China Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons)

Figure 45. Japan Peripherally Acting Anti-Obesity Drug Sales and Growth Rate



(2019-2024) & (Kilotons) Figure 46. South Korea Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons) Figure 47. India Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons) Figure 48. Southeast Asia Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons) Figure 49. South America Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (Kilotons) Figure 50. South America Peripherally Acting Anti-Obesity Drug Sales Market Share by Country in 2023 Figure 51. Brazil Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons) Figure 52. Argentina Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons) Figure 53. Columbia Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons) Figure 54. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (Kilotons) Figure 55. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Market Share by Region in 2023 Figure 56. Saudi Arabia Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons) Figure 57. UAE Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons) Figure 58. Egypt Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons) Figure 59. Nigeria Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons) Figure 60. South Africa Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2019-2024) & (Kilotons) Figure 61. Global Peripherally Acting Anti-Obesity Drug Sales Forecast by Volume (2019-2030) & (Kilotons) Figure 62. Global Peripherally Acting Anti-Obesity Drug Market Size Forecast by Value (2019-2030) & (M USD) Figure 63. Global Peripherally Acting Anti-Obesity Drug Sales Market Share Forecast by Type (2025-2030) Figure 64. Global Peripherally Acting Anti-Obesity Drug Market Share Forecast by Type (2025 - 2030)



Figure 65. Global Peripherally Acting Anti-Obesity Drug Sales Forecast by Application (2025-2030)

Figure 66. Global Peripherally Acting Anti-Obesity Drug Market Share Forecast by Application (2025-2030)



I would like to order

Product name: Global Peripherally Acting Anti-Obesity Drug Market Research Report 2024(Status and Outlook)

Product link: https://marketpublishers.com/r/G995E7C283AAEN.html

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Into en arketpublishers

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/G995E7C283AAEN.html</u>